One Weak Spot, One Upgrade: Wells Fargo on Zimmer Biomet (ZBH)
Wells Fargo upgraded Zimmer Biomet (ZBH) to Overweight with a $123 price target, citing growth in hips and other products. ZBH's knee sales fell 3.1% in Q3 2026, but the company raised its 2026 EPS guidance to $8.50-$8.60. The Fed may raise rates in December, with officials divided on the size of the hike.
How this was made

The 30-second read
Why it matters
For ZBH, the actionable element is the Wells Fargo rating upgrade and raised price target, anchored to a specific product catalyst (Monogram robot) intended to address the company’s weakest segment (knees).
Market read
Traders can use the upgrade and target change to reassess near-term sentiment and the probability-weighting of the knee recovery catalyst.
What to watch
The article notes knee sales fell 3.1% in Q3 2026 while hips grew 6.0%, so investors may still need evidence that knees are stabilizing before the 2027 robot launch.
Background
The piece frames Zimmer Biomet’s analyst upgrade within a broader market narrative about Fed rate expectations and higher Treasury yields.
Ticker impact
Wells Fargo upgraded Zimmer Biomet to Overweight on Nov. 17, lifting its price target to $123 and citing the Monogram knee robot as the fix.
Likely near-term support as traders price in improved knee recovery expectations tied to the Monogram launch timeline.
The article provides a specific analyst action (rating change and price target) plus a concrete operational thesis (knee weakness, Monogram launch) that can influence positioning ahead of future updates.
Market effects
Orthopedic medtech sentiment may improve modestly if investors view robotics as a credible catalyst for knee demand stabilization.
No direct regional transmission beyond general US rate and equity risk sentiment discussed in the piece.
Limited, as the core catalyst is company-specific (Monogram launch) and the macro context is US-focused.
Counterpoint
The upgrade may be premature if knee weakness persists longer than the Monogram timeline, making the catalyst more speculative than the rating implies.
Key entities
- companyZimmer Biomet
Orthopedic implant and sports medicine company; subject of the Wells Fargo upgrade and product-catalyst thesis.
- analyst_firmWells Fargo
Upgraded ZBH to Overweight and raised its price target to $123, citing Monogram robot for knee recovery.
- product_catalystMonogram robot
Robotic system expected to launch in the first half of 2027, positioned as the fix for knee weakness.




